Atezolizumab + Bevacizumab for Liver Cancer
(AB7 Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on systemic immunosuppressive medications, you must stop them 6 weeks before starting the trial, unless they are low-dose corticosteroids or certain other exceptions.
What data supports the effectiveness of the drug combination Atezolizumab and Bevacizumab for liver cancer?
Is the combination of Atezolizumab and Bevacizumab safe for treating liver cancer?
The combination of Atezolizumab and Bevacizumab has been studied for liver cancer and is generally considered safe, but it can cause side effects like high blood pressure, tiredness, and protein in the urine. Bleeding was more common in patients taking this combination compared to another treatment, so monitoring is recommended.26789
How is the drug combination of atezolizumab and bevacizumab unique for liver cancer treatment?
The combination of atezolizumab and bevacizumab is unique because it is the new standard first-line treatment for advanced liver cancer, offering improved survival compared to previous options like sorafenib. This combination therapy represents a significant advancement in managing liver cancer across various stages.1251011
What is the purpose of this trial?
This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
Research Team
Howard S. Hochster
Principal Investigator
Rutgers Cancer Institute of New Jersey
Eligibility Criteria
This trial is for adults with advanced liver cancer (Hepatocellular Carcinoma) who haven't had systemic therapy before. They should have a specific level of liver dysfunction (Child-Pugh B7 or B8), be able to perform daily activities with little help, and agree to use contraception. People can't join if they're on high-dose steroids, have certain heart or lung conditions, uncontrolled other diseases, or are expected to need treatment for another cancer within two years.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive atezolizumab 1,200 mg IV and bevacizumab 15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Atezolizumab
- Bevacizumab
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kristen Spencer
Lead Sponsor
Howard S. Hochester
Lead Sponsor
Howard S Hochster
Lead Sponsor
Genentech, Inc.
Industry Sponsor
Ashley Magargee
Genentech, Inc.
Chief Executive Officer since 2024
MBA from Harvard University, BA from Princeton University
Levi Garraway
Genentech, Inc.
Chief Medical Officer since 2021
MD, PhD
Rutgers Cancer Institute of New Jersey
Collaborator